CEO John Graham to Present at UBS Global Life Sciences Conference,
Rodman & Renshaw Healthcare Conference, and BioPharm America/
MassBio Investors Forum

Singapore - August 26, 2010 - Invida Group Pte Ltd, the leading specialty biopharmaceutical company focused on the commercialization of healthcare products throughout Asia Pacific, today announced that John Graham, CEO will present at three significant U.S. conferences in September.  At these conferences, John will provide an update on Invida's 2010 performance, strategic alliances, and overall capabilities as well as outlining initiatives for the coming year.
Graham commented, "It is a great privilege to have the opportunity to participate in these select conferences.  As 2010 draws to a close, we are looking forward to updating key stakeholders on our progress this year as well as our outlook for 2011.  We are also focused on the opportunity to initiate and develop relationships with our peers in the industry who will be present at these meetings."
Rodman & Renshaw Annual Global Investment Conference, New York, NY
Company Presentation:
When: Wednesday, September 15, 2010, 10:00 a.m.
Where: Fahnestock Salon (5th Floor), The New York Palace Hotel

BioPharm America/MassBio Investors Forum, Boston, MA
Company Presentation:
When: Friday, September 17, 2010, 11:00 a.m.
Where: Berkeley Room, The Boston Marriott Copley Place
UBS Global Life Sciences Conference, New York, NY
Company Presentation:
When: Monday, September 20, 2010, 4:30 p.m.
Where: The Grand Hyatt New York

About Invida Group Pte Ltd
Invida improves the lives of patients in the Asia Pacific Region by commercializing a unique and growing portfolio of pharmaceutical products. We do this through our proven brand marketing and sales know-how, strong expertise across a number of key therapeutic categories, and deep experience in all critical Asia Pacific markets. Comprehensive functional capabilities provide rapid market access delivered by our passionate team of professionals.

With 4,000 employees in 13 markets in Asia Pacific, Invida operates across the commercial value chain from regulatory approval and product launch to lifecycle management. We manage a portfolio of proprietary healthcare brands as well as licensed products from small biotech firms and large multinational companies. Partnering is a critical component of Invida's business model. We collaborate closely with our partners in developing effective strategies and put our extensive experience behind maximizing the potential of the assets entrusted to us.

LaVoie Group, Inc.
Liz Pingpank
+1 (978) 745-4200
[email protected]

Suggested Articles

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."

F2G has raised $60.8 million to fund late-phase clinical development of its antifungal agent olorofim and prepare for commercialization.

The deal comes almost two years after Roche dropped the tumor microenvironment modulator after putting it through a clutch of early-phase studies.